Back to Browse Journals » Vascular Health and Risk Management » Volume 8

Everolimus-eluting stents in interventional cardiology

Authors Townsend JC, Rideout P, Steinberg DH

Published Date June 2012 Volume 2012:8 Pages 393—405

DOI http://dx.doi.org/10.2147/VHRM.S23388

Received 28 January 2012, Accepted 21 March 2012, Published 27 June 2012

Jacob C Townsend, Phillip Rideout, Daniel H Steinberg
Division of Cardiology, Medical University of South Carolina, Charleston, SC, USA

Abstract: Bare metal stents have a proven safety record, but limited long-term efficacy due to in-stent restenosis. First-generation drug-eluting stents successfully countered the restenosis rate, but were hampered by concerns about their long-term safety. Second generation drug-eluting stents have combined the low restenosis rate of the first generation with improved long-term safety. We review the evolution of drug-eluting stents with a focus on the safety, efficacy, and unique characteristics of everolimus-eluting stents.

Keywords: everolimus-eluting stents, safety, efficacy

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Advances in stent technologies and their effect on clinical efficacy and safety

Nikam N, Steinberg TB, Steinberg DH

Medical Devices: Evidence and Research 2014, 7:165-178

Published Date: 3 June 2014

Readers of this article also read:

Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients

Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Terleira-Fernández AI, Vargas-Castrillón E, Rocha E

Vascular Health and Risk Management 2013, 9:207-228

Published Date: 8 May 2013

Bioresorbable scaffolds in the treatment of coronary artery disease

Zhang Y, Bourantas CV, Farooq V, Muramatsu T, Diletti R, Onuma Y, Garcia-Garcia HM, Serruys PW

Medical Devices: Evidence and Research 2013, 6:37-48

Published Date: 12 March 2013

Acute idiopathic pericarditis: current immunological theories

Caforio AL, Marcolongo R, Brucato A, Cantarini L, Imazio M, Iliceto S

Research Reports in Clinical Cardiology 2012, 3:49-55

Published Date: 27 September 2012

Usefulness of serum mass spectrometry to identify women diagnosed with higher grades of cervical intraepithelial neoplasia may differ by race

Matthews R, Azuero A, Asmellash S, Brewster E, Partridge EE, Piyathilake CJ

International Journal of Women's Health 2011, 3:185-192

Published Date: 12 July 2011

Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt

Guan P, Lu Y, Qi J, Niu M, Lian R, Hu F, Wu W

International Journal of Nanomedicine 2011, 6:965-974

Published Date: 4 May 2011

New stent design for use in small coronary arteries during percutaneous coronary intervention

Juan F Granada, Barbara A Huibregtse, Keith D Dawkins

Medical Devices: Evidence and Research 2010, 3:57-66

Published Date: 19 October 2010

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009